Early Prediction of Postpartum Glucose Metabolism Abnormalities in Gestational Diabetes Mellitus
Study Details
Study Description
Brief Summary
This project is expected to screen reliable serum markers in pregnant women with gestational diabetes mellitus (GDM) by using metabolic profiling and lipid profiling clinical high-throughput mass spectrometry technology. We intend to build an early pregnancy prediction model for postpartum glucose metabolism abnormalities of GDM. At the same time, this project plans to develop a predictive management system based on this model, so that it can be widely used in clinical detection process, realize the advance of the early warning window period of abnormal glucose metabolism, and provide theoretical guidance for the early postpartum blocking of GDM to the outcome of abnormal glucose metabolism.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Abnormal postpartum glucose metabolism GDM with positive OGTT results at 6-12 weeks postpartum |
Other: Questionnaire survey and specimen collection
A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
|
| Control GDM with negative OGTT results at 6-12 weeks postpartum |
Other: Questionnaire survey and specimen collection
A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
|
Outcome Measures
Primary Outcome Measures
- Serum lipidomics [During the 24-28 geatational weeks.]
The differential serum lipid molecules in serum were detected by the self-developed detection chip, and the markers related to postpartum glucose metabolism abnormalities in GDM were screened. Specimens were collected during the 24-28 geatational weeks.
- Serum metabolomics [During the 24-28 geatational weeks.]
The differential serum metabolism molecules in serum were detected by the self-developed detection chip, and the markers related to postpartum glucose metabolism abnormalities in GDM were screened. Specimens were collected during the 24-28 geatational weeks.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Plan to have routine prenatal examinations and give birth in the research center
-
GDM was diagnosed at 24-28 gestational weeks
-
Singleton pregnancy
-
Without other pregnancy complications
-
Willing to cooperate with the hospital to follow up
Exclusion Criteria:
-
Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy, such as diabetes, heart disease, liver and kidney diseases, thyroid diseases with drug, autoimmune diseases, malignant tumors, AIDS, etc.
-
Fetus has a known deformity or genetic defects
-
Incomplete clinical data
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Women's Hospital School Of Medicine Zhejiang University | Hangzhou | Zhejiang | China | 310006 |
Sponsors and Collaborators
- Women's Hospital School Of Medicine Zhejiang University
Investigators
- Study Director: Zhaoxia Liang, Prof., Women's Hospital School Of Medicine Zhejiang University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB-20220336-R